Barclay ML, et al. - In the present study, researchers compared IBD disease activity in patients in New Zealand with trough concentrations of infliximab and adalimumab utilizing a locally developed enzyme-linked immunosorbent assay (ELISA), and anti-drug antibodies (ADA) using competitive-binding ELISA and homogeneous mobility shift assay (HMSA), to establish threshold concentrations. Study participants were patients with ulcerative colitis (UC) and Crohn’s disease (CD) from Christchurch and Dunedin on anti-TNF drugs > 12 weeks. According to the findings, threshold concentrations of 5mg/L for infliximab and 7mg/L for adalimumab, assessed via the New Zealand ELISA assay, were suggested to support dosing decisions, and these were consistent with results internationally. It was noted that neutralizing (ELISA) as well as non-neutralizing ADA (HMSA) correlated with low drug concentrations.